Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study

OBJECTIVES Evaluate the safety, tolerability and preliminary efficacy of intracoronary (IC) basic fibroblast growth factor (bFGF, FGF-2). BACKGROUND FGF-2 is a heparin-binding growth factor capable of inducing functionally significant angiogenesis in animal models of myocardial ischemia. METHODS Pha...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2000-12, Vol.36 (7), p.2132-2139
Main Authors: Laham, Roger J, Chronos, Nicholas A, Pike, Marilyn, Leimbach, Mark E, Udelson, James E, Pearlman, Justin D, Pettigrew, Roderic I, Whitehouse, M.J, Yoshizawa, Carl, Simons, Michael
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Cardiology. Vascular system
Coronary heart disease
Exercise Test
Feasibility Studies
Female
Fibroblast Growth Factor 2 - administration & dosage
Heart
Humans
Infusions, Intra-Arterial
Magnetic Resonance Imaging
Male
Medical sciences
Middle Aged
Myocardial Ischemia - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES Evaluate the safety, tolerability and preliminary efficacy of intracoronary (IC) basic fibroblast growth factor (bFGF, FGF-2). BACKGROUND FGF-2 is a heparin-binding growth factor capable of inducing functionally significant angiogenesis in animal models of myocardial ischemia. METHODS Phase I, open-label dose-escalation study of FGF-2 administered as a single 20-min infusion in patients with ischemic heart disease not amenable to treatment with CABG or PTCA. RESULTS Fifty-two patients enrolled in this study received IC FGF-2 (0.33 to 48 μg/kg). Hypotension was dose-dependent and dose-limiting, with 36 μg/kg being the maximally tolerated dose. Four patients died and four patients had non-Q-wave myocardial infarctions. Laboratory parameters and retinal examinations showed mild and mainly transient changes during the 6-month follow-up. There was an improvement in quality of life as assessed by Seattle Angina Questionnaire and improvement in exercise tolerance as assessed by treadmill exercise testing (510 ± 24 s at baseline, 561 ± 26 s at day 29 [p = 0.023], 609 ± 26 s at day 57 (p < 0.001), and 633 ± 24 s at day 180 (p < 0.001), overall p < 0.001). Magnetic resonance (MR) imaging showed increased regional wall thickening (baseline: 34 ± 1.7%, day 29: 38.7 ± 1.9% [p = 0.006], day 57: 41.4 ± 1.9% [p < 0.001], and day 180: 42.0 ± 2.3% [p < 0.001], overall p = 0.001) and a reduction in the extent of the ischemic area at all time points compared with baseline. CONCLUSIONS Intracoronary administration of rFGF-2 appears safe and is well tolerated over a 100-fold dose range (0.33 to 0.36 μk/kg). Preliminary evidence of efficacy is tempered by the open-label uncontrolled design of the study.
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(00)00988-8